SOMMERFELD MARK,SCHAEFER HANS LUDWIG,BOSCHEINEN OLIVER,HABERMANN PAUL,RAO ERCOLE,DREYER MATTHIAS
申请号：
IN6325/CHENP/2012
公开号：
IN2012CN06325A
申请日:
2012.07.18
申请国别(地区):
IN
年份:
2014
代理人:
摘要：
The invention is directed to a pharmaceutical composition containing at least one FGF 21 (fibroblast growth factor 21) compound, at least one GLP 1R (glucagon - like peptide -1 receptor) agonist and optionally at least one anti - diabetic drug and/or at least one DPP 4 (dipeptidyl peptidase 4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis in particular diabetes dyslipidemia obesity and/or adipositas.
